VolitionRx Sponsors Important Symposium on Hidradenitis Suppurativa
Highlighting New Advances in Nu.Q Testing
VolitionRx Limited (NYSE AMERICAN: VNRX), a global leader in epigenetics, is thrilled to announce its sponsorship of a significant symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference. This pivotal gathering takes place in Malta and aims to offer invaluable insights into the management of Hidradenitis Suppurativa (HS).
Symposium Overview and Presentation Highlights
The symposium, titled "Empowering Precision-Medicine through NETs Plasma Biomarker-Driven Personalized Treatment," will feature Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD, a noted expert in the field. He is affiliated with ATTIKON University General Hospital in Greece.
Professor Giamarellos-Bourboulis expressed his enthusiasm for the conference, noting, "This year’s EHSF scientific program emphasizes the importance of genetics, providing updates on fundamental research pertinent to diagnosing and managing HS." His session will present groundbreaking data from clinical studies involving Volition's Nu.Q testing.
Nu.Q Testing: A Clinical Breakthrough
During the symposium, Professor Giamarellos-Bourboulis will unveil results from a recent clinical study showcasing how Volition's Nu.Q NETs test can effectively assist in managing HS, a chronic condition that affects approximately 1% of the global population. He remarked, "Our findings reveal that this straightforward blood test simplifies the classification of HS patients, facilitating informed treatment decisions."
With advancements in biological therapies for HS, there’s an evident variation in patient response. Some experience notable improvement, while others may see no benefit or even exacerbation of symptoms. This disparity underscores the vital role of tailored treatments, a core focus of the symposium.
Future Directions in HS Research
Looking ahead, Professor Giamarellos-Bourboulis will explore the potential of circulating H3.1 nucleosomes as a biomarker, vital for ongoing and future clinical studies. He expressed a hopeful sentiment: "Our aspiration is to commence trials examining whether Nu.Q NETs can inform both the initiation and discontinuation of treatment.”
Volition's VP of Corporate Alliances and Strategic Partnership, Mr. Remi Rabeuf, echoed this excitement, stating, "It's a privilege to have such a distinguished expert as Professor Giamarellos-Bourboulis present at our symposium."
The Significance of Nu.Q NETs
As a CE-Marked assay designed to detect diseases linked to NETosis, Nu.Q NETs is not only commercially available across 27 European Union member states and three additional EEA countries, but also serves a crucial role in disease management.
This low-cost, easily accessible blood test holds immense potential. With a total addressable market estimated at $3.8 billion, its introduction is expected to revolutionize patient care by enabling earlier detection and monitoring of diseases related to NETosis.
Additional Presentation at the Conference
A complementary poster titled "Change of Neutrophil Extracellular Traps (NETs) Blood Levels to Surrogate Response to Treatment in Hidradenitis Suppurativa" is also scheduled for presentation during the conference, further highlighting the critical role of Nu.Q testing.
About Hidradenitis Suppurativa
Hidradenitis suppurativa is a challenging and often painful skin condition characterized by recurring abscesses and scarring. Affecting a notable portion of the population, awareness and early diagnosis are paramount for effective management. Symptoms can significantly detract from patient quality of life, emphasizing the importance of ongoing research and improved therapeutic approaches.
About Volition
Volition is dedicated to the advancement of epigenetics, striving to improve health outcomes through early detection of diseases. The company focuses on developing blood tests that aid in the diagnosis, monitoring, and treatment of various conditions, including cancers and diseases associated with NETosis. Volition's research facilities are located in Belgium, with additional innovation laboratories in the U.S. and London.
Frequently Asked Questions
What is the main focus of the symposium sponsored by Volition?
The symposium focuses on Precision-Medicine through NETs Plasma Biomarkers, specifically in relation to Hidradenitis Suppurativa.
Who is presenting at the Volition-sponsored symposium?
Professor Evangelos J. Giamarellos-Bourboulis, a respected physician from Greece, is the presenter.
What is Nu.Q testing and its significance?
Nu.Q testing is a blood test that helps in the classification and management of Hidradenitis Suppurativa, offering a personalized treatment approach.
What are the potential benefits of Nu.Q NETs?
Nu.Q NETs could enable better classification of HS patients, guiding treatment decisions and potentially improving outcomes.
What is Volition's mission?
Volition aims to enhance health outcomes through early detection and monitoring of diseases using innovative blood tests.
